Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models

Wang, Zebin; Sun, Kaiming; Xiao, Yonghong; Feng, Bin; Mikule, Keith; Ma, XiaoYan; Feng, Ningping; Vellano, Christopher P.; Federico, Lorenzo; Marszalek, Joseph R.; Mills, Gordon B.; Hanke, Jeffrey; Ramaswamy, Sridhar; Wang, Jing

doi:10.1038/s41598-019-38534-6

Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models

PARP inhibitors have been proven clinically efficacious in platinum-responsive ovarian cancer regardless of BRCA1/2 status and in breast cancers with germline BRCA1/2 mutation. However, resistance to PARP inhibitors may preexist or evolve during treatment in many cancer types and may be overcome …